CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$11.91
-0.09 (-0.75%)
Open$12.36
Previous Close$12.00
Day High$12.58
Day Low$11.73
52W High$26.95
52W Low$3.55
Volume—
Avg Volume1.24M
Market Cap1.00B
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+281.2% upside
Current
$11.91
$11.91
Target
$45.40
$45.40
$29.32
$45.40 avg
$54.46
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |
| Rev Growth | +19.0% | -0.6% | +17.7% |
| Debt/Equity | 0.54 | 0.42 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |